市場調査レポート
商品コード
1381102
ズレッソ(ブレキサノロン)医薬品の考察と市場予測 - 2032年ZULRESSO Drug Insight and Market Forecast - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
ズレッソ(ブレキサノロン)医薬品の考察と市場予測 - 2032年 |
出版日: 2023年11月01日
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 1~3営業日
|
当レポートでは、米国のズレッソ(ブレキサノロン)市場について調査分析し、作用機序、用法と用量、研究開発活動に関する考察や、市場予測などを提供しています。
“"ZULRESSO Drug Insight and Market Forecast - 2032" report provides comprehensive insights about ZULRESSO for postpartum depression (PPD) in the United States. A detailed picture of the ZULRESSO for PPD in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the ZULRESSO for PPD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ZULRESSO market forecast analysis for PPD in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in PPD.
ZULRESSO (brexanolone) is a neuroactive steroid gamma-aminobutyric acid (GABA), a receptor-positive modulator indicated for treating PPD in adults. ZULRESSO was granted a Priority Review and was designated a breakthrough treatment by the FDA. ZULRESSO is available to patients only through a Risk Evaluation and Mitigation Strategy (REMS) program and must be administered at a certified healthcare facility. In addition, patients must be monitored continuously during the drug infusion due to the risk of serious side effects. The mechanism of action of brexanolone in the treatment of PPD in adults is related to its positive allosteric modulation of GABAA receptors. ZULRESSO potentiated GABA-mediated currents from recombinant human GABAA receptors in mammalian cells expressing α1B2γ2 receptor subunits, α4B3δ receptor subunits, and α6B3δ receptor subunits. Notably, ZULRESSO (brexanolone) is the first drug approved by the US FDA specifically for PPD in adults.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
This report provides a detailed market assessment of ZULRESSO for postpartum depression (PPD) in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of ZULRESSO for PPD covering trial interventions, trial conditions, trial status, start and completion dates.